Abstract
Rationale
Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that has medical indications but is also used as a recreational drug. Previous research has found persisting cognitive and psychotogenic effects of ketamine in chronic abusers of this drug 3 days after an acute dose.
Objective
The present study aimed to investigate the effects of ketamine on two processes related to drug abuse, response inhibition and reinforcement, and to examine whether an acute dose of ketamine produced residual cognitive effects in healthy volunteers.
Methods
Fifty-four healthy volunteers were given an 80-min infusion of one of two doses (0.4, 0.8 mg kg−1) of ketamine or placebo. Subjects completed a battery of tests at three time points: pre-infusion, during the infusion and 3 days later at follow-up. The battery consisted of tests of episodic and semantic memory, schizophrenic-like and dissociative symptoms, response inhibition and measures of subjective effects, including mood, bodily symptoms and enjoyment of and desire for the drug.
Results
Ketamine acutely impaired response inhibition and had related biphasic effects on the subjective reinforcing effects of the drug. Ketamine also acutely impaired episodic but not semantic memory and increased schizophrenic-like and dissociative symptoms. No residual cognitive effects were observed 3 days following an acute dose.
Conclusions
The lack of residual effects in healthy volunteers on day 3 indicates that impairments found on day 3 in ketamine abusers are chronic effects. The abuse of ketamine may be related to its capacity both to reinforce and to decrease response inhibition.
Similar content being viewed by others
References
Abel KM, Allin MPG, Hemsley DR, Geyer MA (2003) Low dose ketamine increases pre-pulse inhibition in healthy men. Neuropharmacology 44:729–737
Adler CM, Goldberg TE, Malhotra AK, Breier A (1998) Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biological Psychiatry 43:811–816
Ahmed SN, Petchovsky L (1980) Abuse of ketamine. Br J Psychiatry 137:303
Battig WF, Montague WE (1969) Category norms of verbal items in 56 categories. A replication and extension of the Connecticut category norms. J Exp Psychol 80:1–46
Beck AT (1978) The Beck Depression Inventory (BDI). The Psychological Corporation. Harcourt Brace Jovanovitz Inc, USA
Bernstein E, Putnam FW (1986) Development, reliability and validity of a dissociation scale. J Nerv Ment Dis 174:727–735
Bond AJ, Lader MH (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218
Bremner JD, Krystal JD, Putman FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician Administered Dissociative States Scale (CADDS). J Traumatic Stress 11:125–136
Burgess P, Shallice T (1997) The Hayling and Brixton Tests. Thames Valley Test Company., Bury St. Edmunds, UK
Cornish JL, Duffy P, Kalivas PW (1993) A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behaviour. Neuroscience 93:1359–1367
Curran HV, Monaghan L (2001) In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 96:749–760
Curran HV, Morgan CJA (2000) Cognitive, dissociative and psychotogenic effects of ketamine on recreational users on the night of drug use and 3 days later. Addiction 95:575–590
Di Chiara G (1999) Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 375:13–30
Ellison G (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilipine as both behavioural and anatomical models of the dementias. Brain Res Rev 20:250–267
Finn PR, Justus A, Mazas C, Steinmetz JE (1999) Working memory, executive processes and the effects of alcohol on Go/No-Go learning: testing a model of behavioral regulation and impulsivity. Psychopharmacology 146:465–472
Giancola PR (2000) Executive function: a conceptual framework for alcohol related aggression. Exp Clin Psychopharmacol 8:576–597
Giancola PR, Moss HB, Martin CB, Kirisci L, Tarter RE (1996) Executive cognitive functioning predicts reactive aggression in boys at high risk for substance abuse: a prospective study. Alcohol Clin Exp Res 20:740–744
Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642–1652
Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642–1652
Grinspoon L, Bakalar JB (1997) Psychedelic drugs reconsidered. Basic Books, New York
Harborne GC, Watson FL, Healy DT, Groves L (1996) The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 10:134–140
Harris EW, Ganong AH, Cotman CW (1984) Long term potentiation in the hippocampus involves activation of N-methyl-d-aspartate receptors. Brain Res 323:132–137
Hetem LAB, Danion JM, Diemunsch P, Brandt C (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152:283–288
Hewitt DJ (2000) The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 16:S73–S79
Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R (2003) Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44:324–341
Hurt PH, Ritchie EC (1994) A case of ketamine dependence. Am J Psychiatry 151:779
Jansen KLR (1990) Ketamine: can chronic use impair memory? Int J Addict 25:133–139
Jansen KLR (2001) Ketamine: dreams and realities. Multidisciplinary association for psychedelic studies (MAPS), Sarasota, USA
Javitt D, Zukin S (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308
Kamaya H, Krishna PR (1987) Ketamine addiction. Anaesthesiology 67:861–862
Kirk JM, Doty P, de Wit H (1998) Effects of expectancies on subjective responses to oral delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 59:287–293
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the non-competitive NMDA-antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199–214
Krystal JH, Karper LP, Bennett A, D’Souza DC, Abi-Dargham A, Morrisey K, Charney DS (1998a) Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213–299
Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998b) Dose-related ethanol–like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 55:354–360
Krystal JH, D’Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB, Vegso S, Heninger GR, Charney DS (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145:193–204
Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D’Souza DC, Lipschitz D, Abi-Dargham A, Charney DS (2000) Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47:137–143
Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869–872
Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9–19
Layer RT, Kaddis FG, Wallace L (1993) The NMDA-receptor antagonist MK-801 elicits conditioned place preference in rats. Pharmacol Biochem Behav 44:245–247
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301–307
Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141–150
Marquis KL, Webb MG, Moreton JE (1989) Effects of fixed ratio size and dose on phencyclidine self-administration by rats. Psychopharmacology 97:179–182
Mixmag (2001) The Mixmag drug survey 2000: the world’s biggest drug survey. Mixmag, 84–103. London, UK, Emap
Mixmag (2002) The Mixmag drug survey 2001: the world’s biggest drug survey. Mixmag, 84–103. London, UK, Emap
Moretti R, Hassan SZ, Goodman LI, Meltzer HY (1984) Comparison of ketamine and thiopental in healthy volunteers: effect on mental status, mood and personality. Anesth Analg 63:1087–1096
Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV (2003) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology (in press)
Newcomer JW, Krystal JH (2001) NMDA Receptor regulation of memory and behaviour in humans. Hippocampus 11:529–542
Newcomer JW, Farber NB, Jevtovic–Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-Induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118
Olney J, Labruyere J, Wang G, Wozniak D, Price MT, Sesma M (1991) NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254:1515–1518
Siegel RK (1978) Phencyclidine and ketamine intoxication: a study of recreational users. In: Peterson RC, Stillman R (eds) Phencyclidine abuse: an appraisal. National Institute on Drug Abuse Research Monograph. NIDA, Rockville, Maryland, pp 119–140
Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simokowitz P, Hurley A, Cooper T, Volkow ND, Cancro R (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C raclopride in normal human subjects. Neuropsychopharmacology 18:18–25
Spielberger C (1983) State-trait anxiety inventory (form Y). Palo Alto, California, Mind Garden. Ref Type: Pamphlet
Weingartner H (2000) Metaphors and models of executive functioning: comment on Giancola. Exp Clin Psychopharmacol 8:609–611
Wilson B, Cockburn J, Baddeley A (1985) The Rivermead behavioural memory test. Thames Valley Test Company, Bury St. Edmunds, UK
Winger G, Palmer RK, Woods J-H (1989) Drug-reinforced responding: rapid determination of dose-response functions. Drug Alcohol Depend 24:135–142
Zukin SR, Zukin RS (1979) Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A 76:5372–5376
Acknowledgments
C.J.A.M. was supported by a Medical Research Council (UK) studentship. This study was aided by a grant to H.V.C. from the University of London UK Central Research Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morgan, C.J.A., Mofeez, A., Brandner, B. et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose–response study. Psychopharmacology 172, 298–308 (2004). https://doi.org/10.1007/s00213-003-1656-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1656-y